The global Deep Brain Stimulation (DBS) Devices Market, valued at USD 1.14 billion in 2022, is anticipated to witness substantial growth, with forecasts indicating a rise to USD 2.23 billion by 2030. This growth is expected to occur at a robust compound annual growth rate (CAGR) of 9.9% during the forecast period spanning from 2023 to 2030.
Deep Brain Stimulation (DBS) is a neurosurgical procedure that involves the implantation of a medical device, commonly referred to as a neurostimulator or brain pacemaker, to deliver electrical impulses to specific areas of the brain. DBS is used to treat a range of neurological disorders, including Parkinson's disease, essential tremor, dystonia, and obsessive-compulsive disorder (OCD), among others.
Get Sample PDF @ https://www.snsinsider.com/sample-request/3335
Key Players
The major key players are, Nevro Corporation, Abbott Laboratories, Neuronetics Inc., Aleva Neurotherapeutics SA, Beijing PINS Medical Co., Ltd., LivaNova PLC and others.
KEY SEGMENTS
By Product
-
Single Channel
-
Dual Channel
By Application
-
-
Pain Management
-
Epilepsy
-
Essential Tremor
-
Obsessive-Compulsive Disorder (OCD)
-
Depression
-
Dystonia
-
Parkinson’s Disease
-
Others
-
By End Use
-
-
Hospitals
-
Neurology Clinics
-
Ambulatory Surgical Centres
-
Research Centres
-
Key factors driving the growth of the Deep Brain Stimulation Devices Market include:
-
Rising Prevalence of Neurological Disorders: The increasing incidence and prevalence of neurological disorders, such as Parkinson's disease and essential tremor, particularly among aging populations, are driving the demand for Deep Brain Stimulation devices as a viable treatment option.
-
Advancements in DBS Technology: Ongoing advancements in DBS technology, including improvements in electrode design, surgical techniques, and programming algorithms, are enhancing the efficacy, safety, and long-term outcomes of DBS therapy, leading to higher adoption rates.
-
Expanding Indications for DBS Therapy: The expanding scope of DBS therapy beyond Parkinson's disease to include other neurological conditions, such as epilepsy, depression, and Alzheimer's disease, is broadening the potential patient population and driving market growth.
-
Growing Awareness and Acceptance: Increasing awareness among patients and healthcare professionals about the benefits of DBS therapy, coupled with greater acceptance of neurostimulation techniques as a mainstream treatment modality, is fueling market expansion.
The forecast period of 2023-2030 is expected to witness continued research and development activities aimed at advancing DBS technology, optimizing patient selection criteria, and exploring new indications for DBS therapy across a wider range of neurological disorders.
Geographically, North America currently dominates the Deep Brain Stimulation Devices Market, attributed to the presence of leading healthcare infrastructure, high adoption rates of innovative medical technologies, and significant investments in neurostimulation research and development. However, regions such as Europe, Asia Pacific, and Latin America are poised for substantial growth opportunities, driven by increasing healthcare expenditure and rising demand for advanced neurological treatments.
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Akash Anand – Head of Business Development & Strategy
Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)
Website: https://www.snsinsider.com